{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T19:40:24Z","timestamp":1783453224961,"version":"3.55.0"},"reference-count":70,"publisher":"FapUNIFESP (SciELO)","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  Background: Proton pump inhibitors (PPIs) are one of the most prescribed drugs in the world. Frequent use and long-term maintenance of these drugs drew the attention of researchers for sporadic adverse effects reports.  Objective: The purpose of this narrative review is to discuss appropriate data and causality related to these adverse events and PPIs.  Methods: A narrative review was conducted by systematizing information about safety and adverse events on PPIs from 2015 to 2020. A structured search on Pubmed was performed to identify systematic reviews and meta-analysis investigating the following situations: a) gastric cancer; b) micronutrients deficiency; c) acid rebound; d) infections; e) fractures; f) dementia; g) kidney disease; and h) sudden death and cardiovascular changes.  Results: Recent studies have potentially associated PPIs with some adverse events as osteoporosis-related fractures. There are also reports of intestinal infections, including Clostridium difficile, besides poor vitamins absorption and minerals such as vitamin B12, magnesium, and iron. Furthermore, there are some dementia, pneumonia, kidney disease, myocardial infarction, and stroke reports. For kidney diseases, studies consistently suggest that the use of PPI may be associated with an increased risk of adverse kidney events, especially in the elderly, with long-term PPI use and pre-existing kidney disease. Another additional question is whether chronic PPI use would also lead to the onset of gastric cancer. The abrupt discontinuation of PPIs is also related to increased gastric acid production above pre-PPI treatment levels; this phenomenon is called acid rebound.  Conclusion: The key to mitigate adverse effects is the rational use of PPIs at the lowest effective dose and in the shortest possible duration. Although these adverse effects have a potential clinical impact, their causal association is still subject to validation.<\/jats:p>","DOI":"10.1590\/s0004-2803.202202000-40","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T12:12:46Z","timestamp":1657109566000},"page":"219-225","source":"Crossref","is-referenced-by-count":46,"title":["SAFETY OF LONG-TERM PROTON PUMP INHIBITORS: FACTS AND MYTHS"],"prefix":"10.1590","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-6687","authenticated-orcid":false,"given":"Decio","family":"CHINZON","sequence":"first","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0431-451X","authenticated-orcid":false,"given":"Gerson","family":"DOMINGUES","sequence":"additional","affiliation":[{"name":"Universidade do Estado do Rio Janeiro,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0389-4156","authenticated-orcid":false,"given":"Nivia","family":"TOSETTO","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4842-1552","authenticated-orcid":false,"given":"Marcos","family":"PERROTTI","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2022,6]]},"reference":[{"key":"ref1","first-page":"21","article-title":"The mortality risk of proton pump inhibitors in 1.9 million US seniors: an extended cox survival analysis","volume":"13","author":"Baik SH","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1007\/s12325-017-0532-9","article-title":"A review of the novel application and potential adverse effects of proton pump inhibitors","volume":"34","author":"Yu L-Y","year":"2017","journal-title":"Adv Ther"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.2169\/internalmedicine.49.4064","article-title":"Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists","volume":"49","author":"Eid SM","year":"2010","journal-title":"Intern Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"114*21","DOI":"10.1111\/bcpt.13023","article-title":"Side effects of long-term proton pump inhibitor use: a review","volume":"123","author":"Haastrup PF","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref5","first-page":"295","article-title":"The environment and disease: association or causation?","volume":"58","author":"HILL AB","year":"1965","journal-title":"Proc R Soc Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756284819834511","article-title":"Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence","volume":"12","author":"Cheung KS","year":"2019","journal-title":"Ther Adv Gastroenterol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s10620-020-06101-z","article-title":"Microbiome and gastric cancer","volume":"65","author":"Engstrand L","year":"2020","journal-title":"Dig Dis Sci"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0016-5085(00)70412-4","article-title":"Synergistic interaction between hypergastrinemia and helicobacter infection in a mouse model of gastric cancer","volume":"118","author":"Wang TC","year":"2000","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1172\/JCI30111","article-title":"Inflammation, atrophy, and gastric cancer","volume":"117","author":"Fox JG","year":"2007","journal-title":"J Clin Invest"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000199381","article-title":"Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion","volume":"35","author":"Havu N","year":"1986","journal-title":"Digestion"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/apt.12012","article-title":"Gastric carcinoids after long-term use of a proton pump inhibitor","volume":"36","author":"Jianu CS","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-2007-1018130","article-title":"Gastroscopic screening for gastric carcinoids and carcinoma in pernicious anemia","volume":"20","author":"Sj\u00f6blom S-M","year":"1988","journal-title":"Endoscopy"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.3748\/wjg.v25.i17.2058","article-title":"Proton pump inhibitor: The dual role in gastric cancer","volume":"25","author":"Joo MK","year":"2019","journal-title":"World J Gastroenterol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1017\/S1368980009990279","article-title":"Association between vitamin B 12 -containing supplement consumption and prevalence of biochemically defined B 12 deficiency in adults in NHANES III (Third National Health and Nutrition Examination Survey)","volume":"13","author":"Evatt ML","year":"2010","journal-title":"Public Health Nutr"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1001\/jama.2013.280490","article-title":"Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B 12 deficiency","volume":"310","author":"Lam JR","year":"2013","journal-title":"JAMA"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cgh.2012.12.011","article-title":"Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis","volume":"11","author":"Lo W","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/apt.13194","article-title":"Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies","volume":"41","author":"Attwood SE","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"ref18","first-page":"G649","article-title":"Gastrin induces parathyroid hormone-like hormone expression in gastric parietal cells","volume":"312","author":"Al Menhali A","year":"2017","journal-title":"Am J Physiol Liver Physiol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.amjmed.2005.02.007","article-title":"Effects of proton pump inhibitors on calcium carbonate absorption in women: A randomized crossover trial","volume":"118","author":"O\u2019Connell MB","year":"2005","journal-title":"Am J Med"},{"key":"ref20","series-title":"Biochemistry, Iron Absorption","author":"Ems T"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1007\/s10620-011-1589-y","article-title":"Association between proton pump inhibitor use and anemia: a retrospective cohort study","volume":"56","author":"Sarzynski E","year":"2011","journal-title":"Dig Dis Sci"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1253\/circj.CJ-14-0582","article-title":"Use of proton pump inhibitors is associated with anemia in cardiovascular outpatients","volume":"79","author":"Shikata T","year":"2014","journal-title":"Circ J"},{"key":"ref23","article-title":"proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency","volume":"152","author":"Lam JR","year":"2017","journal-title":"Gastroenterology"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015011","article-title":"Does the use of proton pump inhibitors increase the risk of hypomagnesemia","volume":"98","author":"Liao S","year":"2019","journal-title":"Medicine"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5527\/wjn.v5.i2.152","article-title":"Proton-pump inhibitor-induced hypomagnesemia: Current research and proposed mechanisms","volume":"5","author":"William JH","year":"2016","journal-title":"World J Nephrol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/951768","article-title":"Hypomagnesemia induced by long-term treatment with proton-pump inhibitors","volume":"2015","author":"Janett S","year":"2015","journal-title":"Gastroenterol Res Pract"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3748\/wjg.v23.i4.563","article-title":"Micronutrient deficiencies in patients with chronic atrophic autoimmune gastritis: a review","volume":"23","author":"Cavalcoli F","year":"2017","journal-title":"World J Gastroenterol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association","volume":"152","author":"Freedberg DE","year":"2017","journal-title":"Gastroenterology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2042098618809927","article-title":"The risks of long-term use of proton pump inhibitors: a critical review","volume":"10","author":"Jaynes M","year":"2019","journal-title":"Ther Adv Drug Saf"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3109\/00365520903477348","article-title":"Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint","volume":"45","author":"Waldum HL","year":"2010","journal-title":"Scand J Gastroenterol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3109\/00365521.2012.746395","article-title":"Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment","volume":"48","author":"Lodrup AB","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00535-017-1371-9","article-title":"Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth","volume":"53","author":"Su T","year":"2018","journal-title":"J Gastroenterol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/ncp.10181","article-title":"Proton pump inhibitors: risks and rewards and emerging consequences to the gut microbiome","volume":"33","author":"Singh A","year":"2018","journal-title":"Nutr Clin Pract"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/j.1532-5415.1993.tb06759.x","article-title":"Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors","volume":"41","author":"Walker KJ","year":"1993","journal-title":"J Am Geriatr Soc"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nrgastro.2009.128","article-title":"Does PPI therapy predispose to Clostridium difficile infection?","volume":"6","author":"Pant C","year":"2009","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/ajg.2012.179","article-title":"Clostridium difficile -associated diarrhea and proton pump inhibitor therapy: a meta-analysis","volume":"107","author":"Janarthanan S","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/jamainternmed.2017.0212","article-title":"Association of gastric acid suppression with recurrent clostridium difficile infection","volume":"177","author":"Tariq R","year":"2017","journal-title":"JAMA Intern Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.3748\/wjg.v23.i35.6500","article-title":"Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis","volume":"23","author":"Trifan A","year":"2017","journal-title":"World J Gastroenterol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/apt.12875","article-title":"Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study","volume":"40","author":"Min YW","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"7490","DOI":"10.4238\/2015.July.3.25","article-title":"Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis","volume":"14","author":"Xu HB","year":"2015","journal-title":"Genet Mol Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jhep.2014.11.036","article-title":"Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: A multicenter prospective study","volume":"62","author":"Terg R","year":"2015","journal-title":"J Hepatol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00198-015-3365-x","article-title":"Proton-pump inhibitors and risk of fractures: an update meta-analysis","volume":"27","author":"Zhou B","year":"2016","journal-title":"Osteoporos Int"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00198-012-2112-9","article-title":"The effect of proton pump inhibitors on fracture risk: report from the canadian multicenter osteoporosis study","volume":"24","author":"Fraser L-A","year":"2013","journal-title":"Osteoporos Int"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3390\/ijerph16091571","article-title":"Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved","volume":"16","author":"Thong BKS","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"ref45","series-title":"Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors","year":"2011"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11894-010-0141-0","article-title":"Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium","volume":"12","author":"Ito T","year":"2010","journal-title":"Curr Gastroenterol Rep"},{"key":"ref47","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e372","article-title":"Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study","volume":"344","author":"Khalili H","year":"2012","journal-title":"BMJ"},{"key":"ref48","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.11.023","article-title":"Dexlansoprazole and esomeprazole do not affect bone homeostasis in healthy postmenopausal women","volume":"156","author":"Hansen KE","year":"2019","journal-title":"Gastroenterology"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00406-014-0554-0","article-title":"Risk of dementia in elderly patients with the use of proton pump inhibitors","volume":"265","author":"Haenisch B","year":"2015","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"5257285","DOI":"10.1155\/2018\/5257285","article-title":"Proton pump inhibitors and dementia: physiopathological mechanisms and clinical consequences","volume":"2018","author":"Ortiz-Guerrero G","year":"2018","journal-title":"Neural Plast"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamaneurol.2015.4791","article-title":"Association of proton pump inhibitors with risk of dementia","volume":"73","author":"Gomm W","year":"2016","journal-title":"JAMA Neurol"},{"key":"ref52","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.06.061","article-title":"Association between proton pump inhibitor use and cognitive function in women","volume":"153","author":"Lochhead P","year":"2017","journal-title":"Gastroenterology"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/ajg.2017.196","article-title":"No association between proton pump inhibitor use and risk of alzheimer\u2019s disease","volume":"112","author":"Taipale H","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"ref54","doi-asserted-by":"crossref","DOI":"10.1093\/dote\/doaa041","article-title":"Proton pump inhibitors do not increase the risk of dementia: a systematic review and meta-analysis of prospective studies","volume":"33","author":"Desai M","year":"2020","journal-title":"Dis Esophagus"},{"key":"ref55","article-title":"Proton pump inhibitor use and risk of dementia: Systematic review and meta-analysis","volume":"98","author":"Li M","year":"2019","journal-title":"Medicine"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","article-title":"Proton pump inhibitor use and the risk of chronic kidney disease","volume":"176","author":"Lazarus B","year":"2016","journal-title":"JAMA Intern Med"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1681\/ASN.2015121377","article-title":"Proton pump inhibitors and risk of incident ckd and progression to ESRD","volume":"27","author":"Xie Y","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.mayocp.2017.10.022","article-title":"Proton pump inhibitors: review of emerging concerns","volume":"93","author":"Nehra AK","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"ref59","article-title":"Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study","volume":"3","author":"Antoniou T","year":"2015","journal-title":"C Open"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/j.gastro.2017.05.046","article-title":"Association between proton pump inhibitor use and risk of progression of chronic kidney disease","volume":"153","author":"Klatte DCF","year":"2017","journal-title":"Gastroenterology"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","article-title":"Proton pump inhibitor use and the risk of chronic kidney disease","volume":"176","author":"Lazarus B","year":"2016","journal-title":"JAMA Intern Med"},{"key":"ref62","article-title":"Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans","volume":"7","author":"Xie Y","year":"2017","journal-title":"BMJ Open"},{"issue":"365","key":"ref63","doi-asserted-by":"crossref","first-page":"l1580","DOI":"10.1136\/bmj.l1580","article-title":"Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study","volume":"29","author":"Xie Y","year":"2019","journal-title":"BMJ"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/CIRCULATIONAHA.113.003602","article-title":"Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine","volume":"128","author":"Ghebremariam YT","year":"2013","journal-title":"Circulation"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1038\/s41598-017-03069-1","article-title":"Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance","volume":"7","author":"Tommasi S","year":"2017","journal-title":"Sci Rep"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10522-016-9675-3","article-title":"Different transcriptional profiling between senescent and non-senescent human coronary artery endothelial cells (HCAECs) by Omeprazole and Lansoprazole treatment","volume":"18","author":"Costarelli L","year":"2017","journal-title":"Biogerontology"},{"key":"ref67","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCRESAHA.116.308807","article-title":"Proton pump inhibitors accelerate endothelial senescence","volume":"118","author":"Yepuri G","year":"2016","journal-title":"Circ Res"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1161\/CIRCULATIONAHA.106.666008","article-title":"Negative inotropy of the gastric proton pump inhibitor pantoprazole in myocardium from humans and rabbits","volume":"116","author":"Schillinger W","year":"2007","journal-title":"Circulation"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2125.2010.03717.x","article-title":"Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes","volume":"70","author":"Furuta T","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1007\/s10620-009-0960-8","article-title":"Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention","volume":"55","author":"Gupta E","year":"2010","journal-title":"Dig Dis Sci"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":["Seguran\u00e7a dos inibidores de bomba de pr\u00f3tons utilizados a longo prazo: fatos e fantasias"],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0004-28032022000200219&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T02:54:25Z","timestamp":1714704865000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032022000200219&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":70,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["S0004-28032022000200219"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.202202000-40","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"value":"1678-4219","type":"electronic"},{"value":"0004-2803","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}